Skip Navigation


Europace Advance Access originally published online on May 16, 2007
Europace 2007 9(8):681-686; doi:10.1093/europace/eum097
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
9/8/681    most recent
eum097v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Bruch, C.
Right arrow Articles by Gradaus, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bruch, C.
Right arrow Articles by Gradaus, R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


ICD AND MONITORING

Prevalence and prognostic impact of comorbidities in heart failure patients with implantable cardioverter–defibrillator

Christian Bruch*, Chahrebanu Bruch, Jürgen Sindermann, Günter Breithardt and Rainer Gradaus

Department of Cardiology and Angiology, Hospital of the University of Münster, Albert-Schweitzer-Str.33, D-48129 Münster, Germany

Aims This study assessed the prevalence and the prognostic impact of comorbidities in heart failure patients with implantatable cardioverter–defibrillator (ICD).

Methods and results We prospectively enrolled 146 patients with chronic heart failure, an ICD, and systolic dysfunction (mean ejection fraction 29 ± 10%). Cardiac death was chosen as the primary endpoint. Death or appropriate ICD therapy, i.e. antitachycardia pacing/shock due to sustained ventricular tachycardia or ventricular fibrillation, was chosen as the secondary endpoint. Seventy-five patients (52%) had chronic kidney disease (defined as an estimated glomerular filtration rate <60 mL/min/1.73 m2), 39 patients (27%) were anaemic, and 34 patients (23%) had diabetes mellitus. During a follow-up of 663 ± 400 days, 22 patients (15%) died, and 41 patients (28%) received an appropriate ICD therapy. By multivariate Cox analysis, independent predictors of cardiac death were chronic kidney disease, age, and NYHA functional class. Death/appropriate ICD therapy were independently predicted by chronic kidney disease and QRS duration. In the presence of chronic kidney disease, outcome was significantly worse when compared with the absence (event-free survival rate 51 vs. 76%, P < 0.001).

Conclusion In heart failure patients with an ICD, comorbidities are frequent but only the presence of chronic kidney disease is independently associated with increased morbidity and mortality.

Key Words: Chronic heart failure, Implantable cardioverter–defibrillator, Comorbidities, Prognosis


* Correspondence author: Tel: +49 251 83 47684; fax: +49 251 83 45631. E-mail address: bruchc{at}uni-muenster.de

Manuscript submitted 26 February 2007. Accepted after revision 17 April 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
EuropaceHome page
T. Schefer, T. Wolber, C. Binggeli, J. Holzmeister, C. Brunckhorst, and F. Duru
Long-term predictors of mortality in ICD patients with non-ischaemic cardiac disease: impact of renal function
Europace, August 7, 2008; (2008) eun186v1.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.